Skip to main content
Premium Trial:

Request an Annual Quote

Valentis Pockets $14M in Public Offering

NEW YORK, Dec. 27 - Valentis has pocketed $13.8 million in an underwritten public offering of its common stock, the company said on Thursday.


Valentis offered the 6,130,007 shares, and Wells Fargo Van Kasper acted as underwriter.


In October, Burlingame, Calif.-based Valentis gave Pfizer a non-exclusive, research-only license to its GeneSwitch gene-regulation technology.


The GeneSwitch system allows researchers to control the level and duration of selected genes in transgenic animals and cell cultures.

The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.